Clinical Trials Logo

Bladder Neoplasms clinical trials

View clinical trials related to Bladder Neoplasms.

Filter by:

NCT ID: NCT00141531 Completed - Bladder Neoplasms Clinical Trials

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

A non-randomized, open-label phase II study to explore the feasibility, time to recurrence, duration of response and safety of the adjuvant intravesical instillation of EOquin (apaziquone) in patients with high-risk superficial bladder tumors, and the response and duration of response in patients with carcinoma in situ of the bladder.

NCT ID: NCT00101608 Completed - Bladder Cancer Clinical Trials

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium. The safety of this treatment will also be studied.

NCT ID: NCT00077688 Completed - Clinical trials for Carcinoma, Transitional Cell

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Start date: November 2003
Phase: Phase 2
Study type: Interventional

Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium

NCT ID: NCT00001381 Completed - Clinical trials for Carcinoma, Transitional Cell

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Start date: March 1994
Phase: Phase 1
Study type: Interventional

Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.